Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29148977 | 0.94 | HSD17B10 (0.41) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL29149056 | 0.94 | HSD17B10 (0.41) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL6360431 | 0.92 | HSD17B10 (0.40) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL27228973 | 0.90 | SMN1; SMN2 (0.43) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL26907063 | 0.90 | SMN1; SMN2 (0.43) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL38656698 | 0.86 | SMN1; SMN2 (0.38) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL883204 | 0.85 | HSD17B10 (0.42) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL15776522 | 0.85 | HSD17B10 (0.42) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL17654997 | 0.85 | HSD17B10 (0.42) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL21997517 | 0.82 | HSD17B10 (0.36) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102082-A1 | ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260125384-A1 | INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2026-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | GIPR, MC2R, GRPR | HSD17B10 1168/4885CHRM2 1291/4885CHRM1 2165/4885 |
| US-20260125384-A1 | INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | CGAS, GMPS, PRKG1 | HSD17B10 1311/4885CHRM2 1891/4885CHRM1 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.